Integrative Approach Targeting the Vagus Nerve and the NEI System (NEIS). 2d Ed. Part 3 - Applied Osteopathy

Pascal JD Grolaux, BSc, DO, MOst. Dr. (hon) ACoPM will offer the unique, evidence-based and most comprehensive course, so far proposed in Canada and in Europe, on the Integrative Approach Targeting the Vagus Nerve and the Neuroendocrine-immune System (NEIS), including Heart Rate Variability analysis based on short-term EKG and learning on bioelectronic medicine (non-invasive vagus nerve and trigeminal nerve stimulation based on latest scientific evidences).

Important Note

• Part 3 will be onsite, 2 days practice only. Applied osteopathic treatment and its effects on the sympatho-vagal balance as demonstrated by heart rate variability analysis (for Osteopaths ONLY).

Note that only Osteopaths can enroll to the 4 days practice (OMT and tVNS-tTMS)!

TOTAL CEUs EARNED : 14.5 hours

Note: language will be English with French translation if needed.

OBJECTIVES

The Part 3 (IIIa) "Applied Osteopathic Treatment Targeting the Neuroendocrine-immune System " (onsite-practice only) (only for those who have followed the Part 1 and Part 2), will introduce specific general and specific osteopathic treatment that can target the neuroendocrine-immune system through different techniques. We will see how osteopathy will affect heart rate variability (HRV) and therefore the sympatho-vagal balance and more globally affects the psychophysiology and the general physiology of a person.

HRV analysis will be conducted before and after OMT, to see the neurophysiological impact of the treatment or specific technique. This is very original in the osteopthic profession, as we know that osteopthy can help but we rarely measure/demonstrate its physiological effect. We will show you evidence that osteopathy works, that is important for the defence of the profession, via objective and not only subjective measures as HRV can very easily implemented in any osteopathic practice.

At the end of the course "Applied Osteopathic Treatment Targeting the Neuroendocrine-immune System" , the participant will:

• Understand the principles of inhibition
• Understand the importance of the osteopathic centers
• Understand how general and specific treatment can modulate the sympatho-vagal balance
• Conduct HRV analysis based on short-term 3 lead EKG
• Be able to practice HRV analysis on short-term EKG-based and understand its neurophysiolocal effects
• Be able to demonstrate its skills in HRV analysis (performing a EKG mesurement) and interpret it
• Be able to offer a patient an evidence-based treatment plan and assessment plan (based on HRV analysis)

Who Should Attend This Course

This course is designed for Osteopaths who has followed the previous Part 1 and Part 2 of the course.

Practical course: 2 days on site (Please note the dates)

"Applied Osteopathic Treatment Targeting the Neuroendocrine-immune System"

·  Type: Practical course at IOSR (Truro clinic)

·  Language: English with French translation available

·  Participants: Osteopaths

·  Date : 19-20 April 2024

·  Duration: 2 full days

·  Schedule: Friday/Saturday. (9AM-5PM)

·  Cancellation deadline: 4 weeks before course

·  Precondition: Webinar Part 1 and Part 2 must have been completed

Content Practice Part 3:

• Practical: ECG is not prerequisite but recommended.
• Practical: Kubios software pre-installed on PC/Mac is not prerequisite but recommended
• Theory: the osteopathic centers and the principle of inhibition
• Review of applied general and specific treatment, techniques
• Heart rate variability and assessment of the sympatho-vagal balance via short-term 3 leads ECG, analysis via Kubios software
• HRV analysis exercices before and after applied osteopathic treatment. Neurophysiological effects of an applied treatment
• Other natural means to stimulate the neuroendocrine-immune system, the vagus and trigermeminal nerves
• Discussion

SELECTED READINGS

Tracey, K. J. (2002). "The inflammatory reflex." Nature 420(6917): 853-859.

Hosoi, T. and Y. Nomura (2004). "Functional role of acetylcholine in the immune system." Frontiers in Bioscience 9: 2414-2419.

Rosas-Ballina, M., et al. (2008). "Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia." Proceedings of the National Academy of Sciences of the United States of America 105(31): 11008-11013.

d.  Sundman, E. and P. S. Olofsson (2014). "Neural control of the immune system." Advances in Physiology Education 38(2): 135-139.

Chavan, S. S. and K. J. Tracey (2017). "Essential Neuroscience in Immunology." Journal of Immunology 198(9): 3389-3397.

Ventureyra, E. C. (2000). "Transcutaneous vagus nerve stimulation for partial onset seizure therapy. A new concept." Child's Nervous System 16(2): 101-102.

Howland, R. H. (2014). "Vagus Nerve Stimulation." Curr Behav Neurosci Rep 1(2): 64-73.

Dietrich, S., et al. (2008). "[A novel transcutaneous vagus nerve stimulation leads to brainstem and cerebral activations measured by functional MRI]." Biomedizinische Technik 53(3): 104-111.

Das, U. N. (2007). "Vagus nerve stimulation, depression, and inflammation." Neuropsychopharmacology 32(9): 2053-2054.

Miller, M. C. (2006). "What is vagus nerve stimulation?" Harvard Mental Health Letter 22(7): 8.

Buschman, H. P., et al. (2006). "Heart rate control via vagus nerve stimulation." Neuromodulation 9(3): 214-220.

Hirsch, E. F. (1962). "Innervation of the human heart. III. The conductive system." Archives of Pathology 74: 427-439.

Voss, A., et al. (2015). "Short-term heart rate variability--influence of gender and age in healthy subjects." PloS One 10(3): e0118308.

Fornari M, Carnevali L, Sgoifo A. Single Osteopathic Manipulative Therapy Session Dampens Acute Autonomic and Neuroendocrine Responses to Mental Stress in Healthy Male Participants. J Am Osteopath Assoc. 2017 Sep 1;117(9):559-567. doi: 10.7556/jaoa.2017.110. PMID: 28846122.

Cerritelli F, Chiacchiaretta P, Gambi F, Saggini R, Perrucci MG, Ferretti A. Osteopathy modulates brain-heart interaction in chronic pain patients: an ASL study. Sci Rep. 2021 Feb 25;11(1):4556. doi: 10.1038/s41598-021-83893-8. PMID: 33633195; PMCID: PMC7907192.